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Abstract
smartPearls are a dermal delivery system for poorly soluble active agents, consisting of nanoporous silica particles loaded with a
long-term stable, amorphous active agent in its mesopores (2–50 nm). The amorphous state of the active agent is known to increase
dermal bioavailability. For use in marketed products, optimal silica types were identified from commercially available, regulatory
accepted silica. In addition, a scalable production process was demonstrated. The loading of the particles was performed by
applying the immersion–evaporation method. The antioxidant rutin was used as a model active agent and ethanol was applied as the
solvent. Various silica particles (Syloid®, Davisil®) differing in particle size (7–50 µm), pore diameter (3–25 nm) and pore volume
(0.4–1.75 mL/g) were investigated regarding their ease of processing. The evaporation from the silica–ethanol suspensions was per-
formed in a rotary evaporator. The finest powders were obtained with larger-sized silica. The maximum loading staying amorphous
was achieved between 10% and 25% (w/w), depending on the silica type. A loading mechanism was also proposed. The most suit-
able processing occurred with the large-sized Syloid® XDP 3050 silica with a 50 µm particle size and a pore diameter of 25 nm, re-
sulting in 18% (w/w) maximum loading. Based on a 10% (w/w) loading and the amorphous solubility of the active agent, for a
100 kg dermal formulation, about 500 g of loaded particles were required. This corresponds to production of 5 kg of loaded smart-
Pearls for a formulation batch size of a ton. The production of 5 kg (i.e., about 25 L of solvent removal) can be industrially realized
in a commercial 50 L rotary evaporator.
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Introduction
Many interesting active agents in pharma and cosmetics are
poorly soluble. Active agents that are poorly soluble in water
but soluble in lipophilic media can easily be formulated as
creams or gels (e.g., the popular coenzyme Q10). The problems
start when the active agents are poorly soluble both in aqueous
and lipophilic/organic media. Classical examples are antioxi-
dants (e.g., rutin, hesperidin), which are presently en vogue in
cosmetics for antipollution products (e.g., the “molecular
barrier” against reactive oxygen species (ROS), infrared (IR) ra-
diation and blue light from computers) [1,2]. For the delivery of
such molecules, efficient delivery systems are the only
solution, because the application of simple suspensions to the
skin normally does not provide a sufficient dermal bioavail-
ability.
Classic delivery systems such as liposomes [3] or solid lipid
nanoparticles (SLNs) [4,5] do not work because the active
agents do not dissolve in the lipidic phase of these systems. A
simple but very effective approach is to increase the saturation
solubility of these active agents. This leads to an increased con-
centration gradient between the formulation and skin, Cs–Cskin,
and thus to an increased diffusional flux into the skin. More-
over, using complexes with polymers or cyclodextrins,
for example, can be of limited effect because of insufficient
release of the molecules from such complexes (i.e., too high
binding constants) [6,7]. Additionally, many molecules are
not able to form such complexes. A highly effective solution
is the dermal administration of nanocrystals (trade name
smartCrystals®) [8-10]. These materials have been on the
market as commercial dermal cosmetic products since 2007
(e.g., hesperidin, la prairie Switzerland) [11,12]. They can be
considered as the current “gold standard”.
The trick with nanocrystals is that the physicochemical
properties on the micrometer scale differ from those on the
nanometer scale, and this results in distinct changes (e.g., the
saturation solubility distinctly increases) [13]. In general, amor-
phous materials have an even higher Cs than nanocrystalline
materials [14]. Thus, it would be more effective to use active
agents in the amorphous state. However, the amorphous state is
physically unstable. Because of their high free energy, amor-
phous phase materials tend to recrystallize [15], especially in
the presence of liquids [16]. This has hindered the broad appli-
cation of amorphous active agents in dermal formulations. The
company Capsulution (Berlin, Germany) incorporated active
agents in the amorphous state inside the pores of silica particles
with mesopores (2–50 nm) [17] using the technology from
CapsMorph for oral administration [18]. With this, the amor-
phous state could be stabilized over the course of years [19].
Porous silica particles are commercially available, for example,
from Grace, Merck Millipore and Formac [20]. They are
considered nanoporous materials because their pore diameter is
on the nanometer scale [21]. The silica they used had so-called
"mesopores", i.e., pores with dimensions in the range of
2–50 nm. In 2006 this delivery technology was transferred from
the oral to the dermal administration route [22] by applying a
technology called smartPearls [23]. The name was changed to
smartPearls to clearly differentiate them from silica used for
oral administration.
smartCrystals are found in products on the cosmetic market,
because industrial large-scale production is possible and an
industrial supplier is available (Dr. Rimpler GmbH, Germany)
for manufacturers of cosmetics. smartCrystals are crystals of
nanometer dimension, typically 200–400 nm, which can be pro-
duced on a large scale by bead milling or high-pressure homog-
enization. Skin penetration studies showed that the smartPearls
were actually superior to the nanocrystals [8,24,25]. However,
the market introduction in final cosmetic products was blocked
due to the lack of an industrial supplier of active agent-loaded
smartPearls. To establish an industrial supply, an industrially
feasible production method is required, which is the focus of
this work.
Silica particles can be loaded by co-milling [26,27], however,
with this technique, a large portion of the active agents are not
incorporated into the pores. Loading can be performed by
supercritical carbon dioxide processing [28], but it is expensive.
Loading is also possible by the impregnation–evaporation
method [29], but this is less suitable for large-scale production.
In this study, the immersion–evaporation method [30] was
applied and systematically investigated to define large-scale
production parameters for an industry friendly one-step produc-
tion process. Rutin was used as the model active agent because
it has high application potential in cosmetic products as well as
in dermal pharmaceutical products [31]. A loading mechanism
for this industrial process is proposed in this work. In addition,
the concentration of smartPearls in the final dermal products are
estimated based on the achieved loadings and on the solubility
data. This work could serve as a guideline for manufacturers of
dermal products. Different types of silica were investigated
having various parameters (e.g., particle size, pore diameter,




Rutin with a purity of 95% was purchased from Denk Ingredi-
ents (Munich, Germany). Various mesoporous silica particles
(Table 1) with pore diameter of 3 nm (Syloid® AL-1 FP), 6 nm
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Table 1: Silica particles used in this work and their properties according the certificate of analysis (manufacturer: W. R. Grace & Co., USA).
Product code Pore diameter [nm] Specific surface area [m2/g] Pore volume [mL/g] Particle size [µm]
Syloid® XDP 3050 25 300 1.8 50
Syloid® 244 FP 17 380 1.6 3
Syloid® 72 FP 10 370 1.2 5
Davisil® SP53D 6 550 0.9 12
Syloid® AL-1 FP 3 740 0.4 7
(Davisil® LC 60 Å 12 µm), 10 nm (Syloid® 72 FP), 17 nm
(Syloid® 244 FP), and 25 nm (Syloid® XDP 3050) were kindly
provided by Grace GmbH & Co. KG (Worms, Germany).
Ethanol, isopropanol, butanol, acetone, ethyl acetate, aceto-
nitrile and dimethyl sulfoxide (DMSO) in gradient grade were
purchased from VWR (Darmstadt, Germany), and purified
water produced by a Milli-Q system from Merck Millipore
(Darmstadt, Germany) was used.
Methods
Solubility investigation of rutin
To assess the maximum solubility of rutin, rutin suspensions
were prepared with different solvents (dimethyl sulfoxide
(DMSO), ethanol, isopropanol, butanol, acetone, ethyl acetate,
acetonitrile, and water) (n = 1). The suspensions with
20% (w/w) rutin were shaken overnight at room temperature,
centrifuged, filtered and the rutin concentration in the filtrate
was analyzed after dilution in ethanol (by a factor of 100–1000)
by UV spectrophotometry (UV-1700 PharmaSpec, Shimadzu,
China) at 360 nm. The evaluation was conducted by the provi-
ded “UVprobe” software (version 2.21). The concentration was
calculated based on the calibration curves determined in
ethanol.
Particle loading
Prior to loading, the silica particles were dried in an oven at
120 °C for at least 2 h. The saturated rutin solution was pro-
duced by preparing a 2% (w/w) rutin suspension in ethanol
(96 vol %), heating it under agitation to 60 °C for 1 h and
subsequent filtration. After cooling, it was checked that no rutin
crystals precipitated out. The rutin content was determined prior
using the rutin solution for loading. For loading, 3 g of silica
particles were dispersed in a respective volume of rutin ethanol
solution. The volume used depended on how much rutin should
be loaded into the silica particles (increasing amounts of solu-
tion with increased percent of loading). The suspension was
stirred for 5 min to achieve a fine dispersion of the particles.
Then the suspension was placed into a rotary evaporator (Büchi,
Germany). The solvent evaporation took place at 40 ± 2 °C and
150 ± 10 mbar, until a film was formed on the wall of the evap-
oration flask. The evaporation time depends on the amount of
solvent used (i.e., increased evaporation time with an increase
of loading percentage). For removal/minimization of solvent
residues, a secondary drying phase at 40 ± 2 °C and 20 mbar
was performed for 30 min. All fractions presented are weight
fractions unless otherwise stated. Each loading for each type of
silica was performed once.
Differential scanning calorimetry (DSC)
The physical state of the silica particles, the rutin raw active
agent powder and the rutin smartPearls was investigated by
differential scanning calorimetry (DSC, Mettler Toledo GmbH,
Germany) and calculated by the provided STARe software
(version 12.10b). Exact amounts between 1–5 mg of rutin-
loaded silica based on the respective mass of rutin (with a target
of 0.5–1 mg) were weighed in a punctured 40 µL aluminum pan
and sealed (n = 1). The measurements were performed at a
heating rate of 20 K/min between 25 and 300 °C under
80 mL/min nitrogen purge.
X-ray diffraction (XRD)
To determine the amorphous state and possible residual crystal
fractions of rutin in smartPearls, XRD was performed using a
Bruker D8 (Bruker, USA) instrument (n = 1). A scan rate of
0.02°/s (2θ = 2–60°) was applied and the goniometer was
equipped with a Cu anode (Cu Kα, λ= 0.15406 nm) at a voltage
of 40 kV and current of 35 mA.
Light microscopy (LM) and scanning electron
microscopy (SEM)
Light microscope imaging was performed using a Motic micro-
scope (BA210, Motic Deutschland GmbH, Germany) with a
Moticam camera and the software Motic Images Plus at 100,
400, and 1,000-fold magnification. SEM was performed at
10,000-fold magnification using a Zeiss DSM950 (Carl Zeiss
AG, Germany) instrument. The samples were sputter-coated
with gold–palladium in an argon atmosphere at 15–20 kV at
0.05 mbar for four minutes.
Determination of recovery rate
For photometric analysis, a precisely weighed amount of rutin-
loaded silica particles (around 25 mg) was dispersed in 5 mL of
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Figure 1: From left to right: rutin/ethanol solution, silica dispersed in rutin solution attached to the rotary evaporator, result after the first hour of sol-
vent evaporation, and the obtained rutin-loaded silica powder, SP53D (right).
DMSO. DMSO was used because of the high rutin solubility in
this solvent. After 10 min of shaking and 10 min of ultrasonica-
tion the suspension was centrifuged at 10,000 rpm for 10 min
and an aliquot of the supernatant was diluted in ethanol by a
factor of 100. Absorption spectroscopy was performed at
360 nm on a PharmaSpec UV-1700 instrument (Shimadzu,
China). The peaks were evaluated using the PharmSpec soft-
ware “UVprobe” (version 2.21).
High-performance liquid chromatography (HPLC) measure-
ments of the same samples were performed at 25 °C using a
Kontron 400 system (Kontron Instruments GmbH, Germany)
equipped with a 20 µL loop and a Eurosper 100-5 C18 column
(250 × 4 mm, 5 µm particle size) column. Determination was
performed at 360 nm with 20:80 acetonitrile/acetate buffer
(pH 4.8, 0.1 mol/L) as a mobile phase and at a flow rate of
1.25 mL/min. The peaks were evaluated with the provided soft-
ware, KromaSystem 2000 (version 1.82).
Solubility determination of rutin dissolved from
smartPearls
The solubility of the raw rutin active agent powder and the rutin
smartPearls was monitored over one hour in 0.15 molar NaCl
solution using in situ UV–vis measurements (Sirius inForm®,
UK) with a fiber optic collector and a path length of 5 mm. The
0.15 molar NaCl solution was placed in a beaker and the
aqueous phase was tempered to 25 °C. After calibration of the
pH electrode and the UV–vis fiber optic, the sample was
manually added immediately after and the UV–vis measure-
ment with the fiber optic was started. The spectra were
corrected using the Tyndall Rayleigh correction function. The
different concentrations of raw active agent powder and rutin
smartPearls were investigated, limited by a maximum overall
absorption up to 2.5. The pH was determined over the whole
measurement period.
Results and Discussion
Considerations for selection of the
production method/variables
The production method should yield a high loading in the pores
and complete transformation of the active agent into the amor-
phous state, thus co-grinding was excluded as a potential pro-
duction method. Also excluded was supercritical CO2 process-
ing, due to production cost reasons, complexity of the
process and cost of a production unit. Ideally, the processing
method should be a one-step method. This excludes the impreg-
nation–evaporation process, because in many cases one impreg-
nation step is not sufficient to reach the anticipated loading.
Thus, the immersion–evaporation process was selected.
The evaporation time of the solvent removal step ranged from
75 to 180 min, depending on the solvent volume. After the
second drying step, the obtained free flowing, dry powder was
removed. When a film was formed on the glass wall, the film
was removed from the wall using a spatula. Potential aggre-
gates were deaggregated by stirring the powder, whereby the
aggregates were easily dispersed. The results from the process-
ing steps are shown in Figure 1.
The principle of the procedure was to suspend the particles in
an amount of solvent containing the total amount of active
agent to be loaded into the pores of the particles. During the
evaporation process, the concentration of the active agent in-
creases, precipitation takes place, and continues until complete
removal of the solvent. It was expected that precipitation takes
place preferentially in the pores because of the largest available
surface area. Minor precipitation on the outer shell of the parti-
cles as a thin layer represents no problem as long as the active
agent on the surface remains amorphous. It is obvious that in
addition to the inner surface in the pores, localization on the
surface of silica particles also takes place. It is important to
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Figure 2: Macroscopic appearance of rutin-loaded silica powders, with decreasing agglomeration tendency from left to right (see text for details).
avoid the formation of crystals of the active agent on the shell
of the particles. This was checked by light microscopy and
scanning electron microscopy.
To study the suitability of the process, silica particles differing
in particle size, pore diameter and pore volume were selected
(Table 1). The investigation should also provide evidence as to
which particle type is optimal to achieve maximum loading.
Solubility of rutin in solvents
A compromise had to be made between the highest possible
solubility of rutin and the tolerability of the solvent by the skin.
Furthermore, processing parameters such as evaporation tem-
perature were crucial. DMSO was used in previous studies with
the impregnation–evaporation method [24] because it has a high
solubility and thus reduces the number of loading steps. The
disadvantage was the long time required for solvent removal at
high temperatures (>80 °C), which can cause degradation of the
active agent. In addition, it is tedious to remove DMSO effi-
ciently by rotary evaporation. Although DMSO can be found in
products applied to the skin, it is less skin friendly. The effi-
cient removal of critical solvents below the ppm specification is
also a cost factor in the production process. Thus, a different,
more skin-tolerable solvent was desirable.
Table 2 shows the obtained solubility of rutin in the various
tested solvents. Rutin has the highest solubility in DMSO
(17%), as expected, but it was decided to select ethanol as a
compromise. With a maximum of 2%, the rutin solubility is
substantial lower in ethanol than in DMSO, but distinctly higher
Table 2: Solubility of rutin at room temperature in various solvents
(w/w %) and the macroscopic appearance of the solutions.
Solvent Solubility [% (w/w)] Appearance
DMSO 17.05 brown
ethanol 2.09 clear, bright yellow
n-butanol 2.07 clear, bright yellow
isopropanol 1.85 clear, bright yellow
acetone 0.83 pale yellow
ethyl acetate 0.42 mildly cloudy
acetonitrile 0.22 mildly cloudy
water 0.03 cloudy, slight yellow
than in acetone (0.8%) and the other organic solvents. The
rutin/ethanol solution had a clear, yellowish appearance.
Loading of silica particles
Different silica materials (Table 1) were loaded with rutin by
dispersing them in a saturated rutin/ethanol solution and evapo-
rating the solvent in a rotary evaporator, resulting in dry
powders. Nitrogen adsorption/desorption studies were per-
formed, showing little decrease in the pore diameter, but a
reduction of the pore volume, supporting the bottom-to-top
filling hypothesis of the pores [32,33]. Depending on the parti-
cle size and the pore diameter, the powders showed different
macroscopic appearances (Figure 2). The silica AL-1 FP tended
to form aggregates, and possessed particle diameter of 7 µm.
The silica materials with the smallest pore diameter, 244 FP and
72 FP (particle diameter 3 and 5 µm; pore diameter 10 and
17 nm, respectively), showed slight agglomeration. SP53D,
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Figure 3: DSC thermograms of crystalline rutin, unloaded silica, a physical mixture of 5% rutin, to be compared to rutin-loaded SP53D processed with
ethanol (28% and 25%), butanol (28%) and DMSO (35%).
having a medium-sized particle size of 12 µm, showed almost
no agglomeration, and at a higher loading of 28% and
30%, a film formed on the wall of the evaporator glass. The
XDP 3050 particles, having the largest diameter of 50 µm (pore
diameter of 25 nm), showed neither agglomeration nor film for-
mation.
It is known that silica particles become more adhesive with de-
creasing size, which is easily explainable by powder technolo-
gy. With decreasing particle size, the surface and contact area
increase, thus promoting particle–particle interaction. Addition-
ally, with increasing pore diameter, the agglomeration tenden-
cy decreases. The particles with a strong agglomeration tenden-
cy (AL-1 FP) have the smallest pore diameter of 3 nm, and ad-
ditionally, the smallest pore volume. It is assumed that the pore
parameters only play a significant role in agglomeration tenden-
cy when the pore volume is completely filled with active agent
or when the pores are too small; this implies that an over-
loading takes place and the precipitating active agent acts as a
kind of glue between the silica particles. This was assumed for
the AL-1 FP samples since rutin with a molar weight of
610.5 g/mol and a minimum projection area of 9.2 nm2 was
assumed to be too large to efficiently diffuse into the pores prior
to precipitation. Thus, such small pores promote agglomeration
on the outside of the pores. Based on the behavior observed,
silica particles with a larger size, larger pores and larger pore
volume are easier to process on a large scale.
Determination of amorphous-phase content
The degree of amorphous phase of the loading was determined
by performing DSC and XRD. An amount of 5% rutin in the
physical mixture with amorphous unloaded silica was
detectable by DSC. The analysis of the physical mixture of
silica with crystalline rutin powder showed that an amount of
only 3% crystalline rutin was clearly detectable by XRD, while
1.5% was hardly detectable (XRD not shown).
Figure 3 shows the DSC thermograms for the maximum-loaded
silica, SP53D, which was loaded using different solvents and
compared to unloaded silica, rutin and their physical mixture. In
the physical mixture, 5% rutin was clearly detectable. No rutin
peak was detectable for loadings up to 25% with ethanol, 28%
with butanol and 35% with DMSO. Crystalline rutin was
clearly detectable for a 28% loading with ethanol (detectable in
temperature range 175–190 °C). It was thus concluded that the
limit of loading in the amorphous state was 25% using ethanol
as the solvent. As reported by Jin [24], loadings of 32% are
achievable with DMSO using the impregnation–evaporation
method. The same loading, or even higher, can be achieved
using the immersion–evaporation method. However, the immer-
sion–evaporation method is scalable and thus of more practical
relevance. Since DMSO is a difficult to process solvent and
more expensive than ethanol, a loading of 25% using ethanol is
considered favorable.
Figure 4 shows XRD patterns of rutin in comparison to
unloaded amorphous silica, crystalline rutin and their physical
mixture. The respective XRD patterns of rutin-loaded SP53D
silica with ethanol (25% loading), butanol (28% loading) and
DMSO (35% loading) as solvents revealed the amorphous
nature of these samples. A rutin peak was detectable in the
physical mixture with 3% rutin. The crystalline rutin peaks
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Figure 4: XRD of rutin, unloaded silica (SP53D), and a physical mixture (3% rutin) in comparison to the maximum loading with rutin-loaded silica
SP53D using different solvents (ethanol, butanol, DMSO).
Figure 5: DSC thermograms (left) and XRD diffractograms (right) for selected silica nanoparticles, all loaded using ethanol as the solvent for rutin,
showing curves with highest amorphous loading. For 72 FP (10 nm pores) the curves obtained with the overloaded system (25%) are also shown, and
for AL-1 FP, only overloaded curves are presented (pore size 3 nm, 12% and 15% loading).
were only detectable for SP53D loaded with 28% rutin using
ethanol as a solvent, which is in agreement with the DSC data.
Even the silica with a high loading of up to 35% (loaded with
DMSO) was a stable, amorphous material. As mentioned, the
industrial feasibility is more important maximizing the achiev-
able loading. To be on the safe side, 20% loadings produced
with ethanol were used for determination of the saturation solu-
bility, and this is recommended as the maximum loading for
commercial use.
Figure 5 shows a comparison between all investigated silica
samples, where the DSC curves (left) and XRD patterns (right)
are plotted with the highest achievable loading of amorphous
material for each silica type, showing no peaks for appropri-
ately loaded silica samples. Only for 72 FP (the curve with no
peaks (20% loading), and the curve with peaks are plotted
(system overloaded, 25%). For AL-1 FP samples (the silica
with the smallest pore size of 3 nm) only the overloaded curves
are shown (12% and 15%). The comparison between DSC and
XRD reveals that XRD was more sensitive to detecting crys-
tallinity. In all overloaded systems, where peaks could be
detected by XRD, no peaks could be seen in DSC. Thus,
applying both methods in parallel was necessary. In conclusion,
silica with a very small pore size of 3 nm are deemed to be less
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Figure 6: Upper row: light microscopy pictures of silica XDP 3050 unloaded (left), loaded with the maximum amorphous fraction of 18% (middle) and
overloaded silica (20% rutin, right). Lower row: corresponding SEM pictures (from left to right).
suitable. The loading of the other silica materials was generally
between 15% and 25%.
Light microscopy and scanning electron
microcopy
Light microscopy is readily accessible and fast to perform; thus,
it was also used to follow the loading process. Light microsco-
py provides a general overview with one glance. When rutin
crystals are present outside of the silica particles, they should be
easily detectable. Also, it was expected to see changes on the
surface of the silica, i.e., evidence of deposition of rutin.
Figure 6 (upper row) shows exemplarily images of XDP 3050
particles. When unloaded, the silica particles appear translucent
(upper left); loading rutin into the pores results in the coloring
of the particles (upper middle). It is apparent that after loading
some particles are still relatively translucent, while other parti-
cles become light to medium colored, although very dark
colored particles can also be seen. That means that not all parti-
cles are loaded to the same degree, and thus there is a wide
loading distribution among the particles. This is important for
understanding the process. When adding more rutin solution,
the heavily loaded particles will first show a crystalline fraction
(due to rutin crystallizing on the surface). The overloaded
system with 20% rutin (upper right) shows a majority of dark
colored particles.
In Figure 6 (lower low), the SEM of unloaded silica (lower left)
shows a smooth surface, almost free of fine particulate material.
The maximum loaded particles (lower row, middle) show some
fine particulate material on the surface. From light microscopy
it can be concluded that there is a distribution in the degree of
particle loading. Thus, the problem in SEM analysis is to distin-
guish to which particles the microscope is focusing on. In the
sample XDP 3050 with overloaded silica (20% loading, lower
right), the particles can be found with pronounced fine particu-
late material on the surface of some of the 50 µm silica parti-
cles.
In conclusion, light microscopy is a suitable complementary
tool for evaluating the loading process, while SEM provides ad-
ditional insight into the mechanism behind the loading process,
but is not essential for batch monitoring during an industrial
production process.
Based on this analysis, a loading mechanism is proposed
(Figure 7) using the example of a silica material with a pore
volume of 1.8 mL/g. At the beginning (before loading), all
pores are empty (0 mL/g, see the upper graph in Figure 7). As
seen from the light microscopy pictures (after the loading
process), obviously some of the particles remain unfilled (light/
transparent particles), some are partially filled, and some are
heavily filled (very dark particles). This is represented in
Figure 7 in the middle graph. The degree of solvent penetration
into different particles varies, leading to particles remaining
unfilled (at 0 mL/g filling) or particles that are partially or me-
dium filled (0–0.4 and 0.4–0.8 mL/g, respectively). There are
Beilstein J. Nanotechnol. 2019, 10, 1666–1678.
1674
Figure 7: Description of the silica particle loading mechanism showing the distribution of differently filled particles as a function of loading. Upper plot:
in the unloaded state, all particles fall within the 0 mL/g fraction. Middle plot: maximum loading condition where no crystallinity was detectable by
XRD; the particles are filled to various extents, possibly with some being overloaded (>1.8 mL/g). Lower plot: some particles are obviously over-
loaded; the population contains a particle fraction in which detectable crystallization occurred.
also particles with higher pore volume filling (0.8–1.2 and
1.2–1.8 mL/g) and also particles with completely filled pores
(filled volume 1.8 mL), which additionally have rutin on the
surface. This implies that the rutin volume per gram of parti-
cles for these samples is >1.8 mL/g (Figure 7, middle). This
surface material is amorphous, since no evidence of crys-
tallinity was detected.
If too much rutin solution is used and evaporation continues,
rutin continues to precipitate on the surface of completely
loaded particles. When rutin deposits as a thin layer on the sur-
face, the rutin stays amorphous; when the layer thickness in-
creases above a critical threshold, crystallization occurs which
can be detected by DSC/XRD (Figure 7, lower plot). For the
use of the particles on the skin one could even argue that over-
loaded systems can be used, because the vast majority of the
particles contain the amorphous phase active agent.
Loading efficiency – recovery rate
It was also investigated whether the initial content of rutin in
the different particle types could be recovered. The rutin was
Figure 8: Recovered fraction of rutin after extraction from silica SP53D
(left) and 72 FP (right) with rutin loadings of 20%, 25%, 28% and 30%,
as measured with HPLC (blue) and spectrophotometry (green). The
standard deviation is shown as the mean of all measurements (HPLC
n = 2, UV n = 1).
extracted with a solvent, and the amount was determined by
spectrophotometry and HPLC. The coefficient of determination
was 0.9943 for HPLC and 0.9921 for UV spectrophotometric
measurements. Figure 8 shows the amount recovered for two
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Figure 9: In situ determined saturation solubility of rutin raw active agent powder (lower curves, red) and amorphous rutin loaded into silica as smart-
Pearls (upper curves, green) with various rutin concentrations.
silica samples, SP53D and 72 FP, with loadings from 20% to
30%. The SP53D and 72 FP silica are shown because of their
high loading (>20%) and suitability for amorphous rutin stabi-
lization.
At lower loadings (i.e., 20%, 25%) a minor fraction could not
be recovered. It is reported in the literature that, due to the large
surface area, a delayed release takes place, where some active
agent is quite firmly bound to the surface and is thus not re-
leased [34]. Thus, the absolute retrieved amount increases with
increasing loading. Additionally, the higher recovery rates for
samples with a certain crystallinity is remarkable. This could
explain the higher recovery rate at higher loadings of 28–30%.
The silica sample with the smaller pores (3 nm, AL-1 FP)
showed at low maximum loading (12%) and a recovery rate of
only about 35%. The recovery rate was also analyzed by HPLC,
and the recovery fractions are all slightly below, but in agree-
ment with, the values obtained using spectrophotometry, as
shown in Figure 8.
The difference in the results obtained from UV spectrophotom-
etry and HPLC analysis can be explained by the extraction
times applied for HPLC and UV spectrophotometry samples. In
general, a higher recovery rate was found in the spectrophotom-
etry analysis due to the longer extraction time (about 30 min for
HPLC analysis versus 2 h for spectrophotometry). The incom-
plete release of the material from the small pores and the influ-
ence of extraction time is relevant for the in vivo situation.
Dermal formulations are often applied for 10–12 h (e.g.,
morning application to the face, followed by face washing in
the evening). To have a release as complete as possible, larger
pores are thus favorable for dermal products. Apart from the
consequence for dermal delivery, the data show that for better
reproducibility, the extraction procedures need to be exactly
identical.
Solubility determination of rutin dissolved
from smartPearls
The saturation solubility, as reported by Mauludin et al., for
rutin nanocrystals and rutin raw material is about 130 µg/mL
[35]. Thus, the solubility of the raw active agent powder is attri-
buted to the presence of nanometer-sized rutin particles in the
raw material. Measuring the solubility of the rutin raw powder
with the setup used in this study at 25 °C yielded a saturation
solubility from 30 to 70 µg/mL at pH 5.5 ± 0.5 (Figure 9, lower
curves). Apart from the nanometer-sized material, the general
high values reported in the literature can be attributed to disso-
lution in a higher pH (6.8) and at a higher temperature (37 °C)
than that used in this study (pH 5.5 for skin products and
25 °C). Additionally, the in situ measurement with baseline
correction and the 0.15 molar NaCl solution used in this study
also led to differences from the values reported in the literature.
The assumption that nanometer-sized rutin particles are present
in the raw material is supported by the fact that the measured Cs
value increased from 30 to 70 µg/mL with increasing amount of
rutin powder (from 0.28 mg/mL to 2.03 mg/mL) added to the
solvent (i.e., more nanometer-sized rutin was added which dis-
solved and led to this increase in the measured solubility).
In contrast to the rutin powder, in this study, an increased Cs of
about 160 µg/mL was obtained with amorphous rutin dissolved
from smartPearls. This implies an increase by about a factor of
two higher than the respective raw active agent powder. This
higher Cs value leads to an increased concentration gradient be-
tween the dermal formulation and skin and thus to an increased
flux of rutin into the skin.
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The dissolution kinetics of rutin from the smartPearls is much
faster than from the raw rutin powder. With smartPearls, the
solubility saturation is reached after almost 1 min, for the raw
rutin powder, it takes 5–10 min. For the dermal formulation the
kinetics is not relevant, only the saturation solubility, Cs. The
smartPearls are added in the preparation of the dermal formula-
tion, and a saturated state will occur in the formulation. When
applied to the skin, it can be predicted that the rate limiting step
is the slow diffusion of dissolved rutin into the skin. There will
be no difference if the diffused rutin molecules are replaced in
the dermal formulation by faster or slower dissolution.
In vitro skin penetration studies showed an even higher increase
in penetration when a gel with smartPearls was compared to a
gel with rutin powder (pig skin penetration test, tape stripping
[24]). Especially in the deeper skin layers, an increase by a
factor of about four was observed.
Concentration of smartPearls in final market
products
When adding smartPearls to the water phase of a dermal prod-
uct, some portion of the rutin in the pores will dissolve, forming
a supersaturated solution. Some portion must remain undis-
solved in the pores in order to provide a rutin source. When
rutin dissolved in the water phase has penetrated into the skin, it
should be replaced by new rutin molecules dissolving from the
pores. With this scheme, a constant supersaturated state will be
maintained. Based on this, the rutin concentration required for a
dermal product can be calculated.
The measured saturation solubility of rutin from smartPearls is
150 µg/mL (i.e., 0.15 mg/mL). This will be the amount of rutin
that dissolves when adding the smartPearls to the formulation.
In addition, one needs a rutin loading in the pores. Thus, it is
recommended to use about two times the amount dissolved. For
highly penetrating active agents, the required amount stored in
the pores might even be higher. Based on this, a minimum of
about 0.5 mg/mL in the final product is required. Assuming a
low loading of the smartPearls of 10% (w/w), a total of 5 mg of
loaded smartPearls need to be added per mL (g) of product (i.e.,
5 g/1 kg product).
Definition of large-scale production
parameters
Based on this, producing a 100 kg batch requires 500 g of
smartPearls; assuming only 10% loading, this corresponds to
50 g of rutin powder. In the production process, this 50 g of
rutin has to be dissolved in ethanol. Based on an ethanol solu-
bility of 2%, 2.5 kg of ethanol are required. In this rutin solu-
tion, 450 g of unloaded silica particles are dispersed. For evapo-
ration, a rotary evaporator with about 2.5 L solvent evaporation
capacity is required, i.e., a rotary evaporator with a volume of
about 20 L.
Large rotary evaporators are available up to volumes of 200 L
(e.g., from GlasKeller AG, Basel, Switzerland). That means that
in one loading process, 5 kg of smartPearls are sufficient to
produce 1000 kg of final product. This proposed production
scheme indicates that the industrial production of smartPearls is
feasible.
Conclusion
For monitoring and understanding the mechanism behind the
loading process, a combination of DSC and XRD techniques is
most suitable. In this study, XRD was found to be more sensi-
tive to understanding the material crystallinity than DSC.
The particles demonstrated a maximum loading of amorphous-
phase rutin of 25% when loaded using ethanol as the solvent.
With DMSO as the solvent, a loading of up to 35% was
possibly. However, DMSO is difficult to remove because of its
high boiling point, and finally, ethanol is preferable because of
its better skin tolerability, price and ease of processing.
To ensure complete amorphization a loading of 20% rutin is
recommended given that recrystallization of excess rutin was
first detected at loadings ≥28%. The saturation solubility of the
loaded material was found to increase by a factor of two with
just one tenth the amount of amorphous rutin compared to raw
active agent powder.
Light microscopy contributed to the understanding of the
loading process. It efficiently revealed that the pore filling
follows a distribution in the degree of filling (ranging from
unloaded to highly loaded). Only a portion of the particles
achieve complete loading, and these are the particles that tend
to show the first crystalline fractions.
Regarding the ease of processability, as predicted, the smaller
particles (such as AL-1 FP, 7 µm diameter) have a higher ten-
dency to agglomerate, and in combination with their small pore
size of 3 nm, the maximum loading is low (<12%). Better
processability was observed for larger particles with larger
pores and pore volume, where the best results among the silica
materials studied was found with Syloid® XDP 3050.
Due to the solubility properties, the amount of 5 kg loaded
smartPearls required for one ton of final product is relatively
low. However, with an established process, large-scale produc-
tion should be possible using commercially available industrial-
sized 50 L evaporators (i.e., the process is scalable). To repro-
duce the small-scale laboratory results on a large scale, only the
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temperature and vacuum parameters need to be set so that the
same amount of solvent evaporates in a given time (i.e., the
Ostwald–Miers range is satisfied).
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